JSPR250117P10000
- 3.02
- +0.02+0.67%
Jasper Therapeutics Newsroom
Jasper Therapeutics Price Target Cut to $40.00/Share From $60.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $40
Jasper Therapeutics Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $80
RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Promising Efficacy and Safety of Jasper Therapeutics' Briquilimab Boosts Buy Rating
Crude Oil Down 1%; US Weekly Jobless Claims Decline
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
US Stocks Down; Acuity Brands Posts Weak Revenue
Jasper Therapeutics Shares Are Trading Lower. The Company Reported Preliminary Data From Its BEACON Phase 1b/2a Study.
Jasper Therapeutics Says Preliminary Study Data for Urticaria Treatment Show Reduced Disease Activity
Express News | Jasper Therapeutics Inc - Data Supports Commencement of Csu Registrational Program Expected to Commence Second Half of 2025
Express News | Jasper Therapeutics Inc - 66% Maintained Well Controlled Disease at 12 Weeks in 240Mg Cohort
BMO Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $63
Jasper Therapeutics Is Maintained at Market Outperform by JMP Securities
Jasper Therapeutics to Host Virtual Webinar Presenting Preliminary Data From BEACON Study of Briquilimab for Chronic Spontaneous Urticaria
Jasper Therapeutics to Host Webinar to Present Preliminary Data From the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
3 Best Stocks to Buy Now, 1/3/2025, According to Top Analysts